Bill Diplas, MD, PhD

@RGIII zvp 0j

Ryan Coogler’s acceptance speech after winning his first-ever Oscar is worth 1 minute of your time 🙏🏾

So excited to share our latest work with @PedramRazaviMD, @MSKCancerCenter, and Sarat Chandarlapaty out today in @Nature. nature.com/articles/s4158… (1/n)

Delighted to share new work from our lab: CRISPR fusion proteins to boost PRECISE genome editing (TruEditors). We wondered what if we could “turn on” and test every gene in the human genome to accelerate protein design?

We’re excited to welcome Daniel Gomez, MD, MBA, a nationally recognized leader in radiation oncology research and clinical trials for lung and oligometastatic cancers, as the new chair of Radiation Oncology at @Perlmutter_CC! Learn more about Dr. Gomez: bit.ly/4rDQliM

Congratulations to Dr. Luis Diaz, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center(MSK), on receiving the @GustaveRoussy Prize. Each year, the Gustave Roussy Foundation selects a prominent figure whose scientific breakthroughs in cancer diagnosis, treatment, or prevention have significantly improved patient care and advanced our understanding of the disease. 👏

💥💥💥 New(-ish) paper alert 💥💥💥 Metient is a fast and powerful method to reconstruct the migration history of metastatic clones and learn cancer-type specific patterns of metastatic spread, from bulk or single-cell sequencing data. nature.com/articles/s4159…

I’m going Founder Mode on my cancer. Below is Elliot Hershberg’s article about my cancer journey. It gave language to something I’d been doing instinctively over the past year: managing my health in Founder Mode. Manager mode assumes that existing systems will surface the best options. When I was first diagnosed with cancer in 2022, I delegated the crucial analyses and decisions about my care to others. In late 2024, when my cancer reappeared and my doctors told me I had exhausted the standard of care and there were no trials for my situation, I realized that assumption might, quite literally, kill me. Founder Mode was my only option. Founder Mode meant going deep on every diagnostic and treatment option. It meant assembling a team of physicians and scientists to work from first principles to understand what was possible beyond standard protocols. Together, we paved new roads to access the very cutting edge of science and technology. Today, thanks to the efforts of many people around the world and the support of my wife Karen, I currently have no evidence of disease. But my fight with cancer is far from over. My team and I continue to develop treatments and strategies in case it returns. More importantly, I now understand firsthand the challenges patients face in order to secure their own data and necessary treatments, particularly personalized medicines. I increasingly see my role as removing structural barriers—breaking down walls that prevent data, treatments, and technologies from flowing where they’re needed. One of the core principles of the first company I founded, GitLab, was radical transparency, and it’s a principle I am bringing to my cancer care. To that end, I am going to be sharing more about my experiences, my treatments, my data, and what I am building to make the path that I’ve been on easier for others to follow. Please subscribe to my mailing list on sytse.com to stay updated. Lastly, I want to thank those who have been on this journey with me. There have been too many to all thank here but I appreciate every one of you. I did want to mention Jacob Stern, Alfredo Gonzalez, and Jeremiah Wala; the amazing teams at Private Health Management (shoutout to Jenn and Eva) and Willy Hoos and Pathfinder Oncology; Nima Afshar and Private Medical; Sant Chawla and the Sarcoma Oncology Center; John Connolly and his team at the Parker Institute; Will Hudson at Baylor College of Medicine; Kamil Slowikowski for his work on osteosarc.com; and Jeff Tsao, Will Gibson, Ali Samiei, Scott McConnell and the rest of the team at the Briger Foundation for Oncology Research.

Come check out some fun ways to use Vault😎 youtube.com/watch?v=AgQdVO… science.org/doi/10.1126/sc…

Excited to share our new study from the Tabar Lab @MSKNeurosurgery in @Cancer_Cell, where we examine human glioma macrophages and identify a functionally distinct subpopulation. sciencedirect.com/science/articl… #glioma_macrophage #glioma #GBM 1/8

🧵1/4 PATH study(Cohort A) out in @IJROBP – Our trial asks whether undetectable post-operative HPV ctDNA can select OPC candidates for adj RT omission and found high rates of disease recurrence #radonc #hncsm redjournal.org/article/S0360-…

Legendary. Thank you guys 🧡 #RolandGarros

COMEBACK COMPLETE. TITLE DEFENSE COMPLETE. #RolandGarros

I discuss the urgent crisis from the loss of federal support of science in the US and recent clinical gene editing breakthroughs with @WalterIsaacson & @amanpour on @AmanpourCoPBS, airing on @PBS tonight at 11 pm ET, and on @cnni earlier today. Pls share! youtube.com/watch?v=8YhJM6…

In the latest issue! Engineering mtDNA deletions by reconstituting end joining in human mitochondria dlvr.it/TKpTmt

New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.10…

RT @MSKCancerCenter: Congratulations to the MSK-IMPACT team at MSK for receiving the American Association for Cancer Research (AACR) Team S…

Thank you to Dr. Agnel Sfeir @MSKCancerCenter for presenting our @YaleCancer Distinguished Lecture on mito-nuclear crosstalk and how mitochondrial and nuclear genomes co-evolve, adapt, and communicate to ensure cellular homeostasis. View her talk now youtube.com/watch?v=-uqQj-…. @SmilowCancer @YaleMed @YNHH

The Chamessian Lab @WashUPain is recruiting a #postdoctoral research associate to build on the foundational findings from our recent preprint showing that ion channels can be degraded by PROTACs. #TPD #PROTAC #drugdiscovery #pain #ionchannels. We're a fun group with an ambitious mission and incredibly exciting work to do. Join us! Paper: biorxiv.org/content/10.110…

A new study by @Chris_JacksonMD & @DanHigginsonMD identified the optimal dose of a type of targeted radiation used to treat people with cancer that has spread to their spine. These new recommendations minimize the risk of developing a complication during therapy known as myelitis. Learn more⬇️ jamanetwork.com/journals/jamao…

1/ 🚨New paper on ecDNAs from our lab! We reveal a strategy to engineer extrachromosomal DNA (ecDNA) amplifications in cells & mice. Let's dive in! 🧵👇 nature.com/articles/s4158…